AU717431B2 - Muscarinic antagonists - Google Patents

Muscarinic antagonists Download PDF

Info

Publication number
AU717431B2
AU717431B2 AU34953/97A AU3495397A AU717431B2 AU 717431 B2 AU717431 B2 AU 717431B2 AU 34953/97 A AU34953/97 A AU 34953/97A AU 3495397 A AU3495397 A AU 3495397A AU 717431 B2 AU717431 B2 AU 717431B2
Authority
AU
Australia
Prior art keywords
compound
group
alkyl
cognitive
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34953/97A
Other languages
English (en)
Other versions
AU3495397A (en
Inventor
Wei K. Chang
Sundeep Dugar
Joseph A Kozlowski
Derek B Lowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU3495397A publication Critical patent/AU3495397A/en
Application granted granted Critical
Publication of AU717431B2 publication Critical patent/AU717431B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU34953/97A 1996-07-01 1997-06-26 Muscarinic antagonists Ceased AU717431B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67439196A 1996-07-01 1996-07-01
US08/674391 1996-07-01
PCT/US1997/010696 WO1998000412A1 (en) 1996-07-01 1997-06-26 Muscarinic antagonists

Publications (2)

Publication Number Publication Date
AU3495397A AU3495397A (en) 1998-01-21
AU717431B2 true AU717431B2 (en) 2000-03-23

Family

ID=24706404

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34953/97A Ceased AU717431B2 (en) 1996-07-01 1997-06-26 Muscarinic antagonists

Country Status (12)

Country Link
EP (1) EP0912534B1 (OSRAM)
JP (2) JP2000514060A (OSRAM)
KR (1) KR20000022380A (OSRAM)
AT (1) ATE224884T1 (OSRAM)
AU (1) AU717431B2 (OSRAM)
CA (1) CA2258044C (OSRAM)
DE (1) DE69715865T2 (OSRAM)
ES (1) ES2179353T3 (OSRAM)
HU (1) HUP9904167A3 (OSRAM)
IL (1) IL127858A0 (OSRAM)
NZ (1) NZ333322A (OSRAM)
WO (1) WO1998000412A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726736D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Chemical compounds
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU1874500A (en) * 1998-12-24 2000-07-31 Astrazeneca Ab 1,4-diazacycloheptane derivatives useful in the treatment of neurological disorders
GB9914015D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
GB9900078D0 (en) * 1999-01-05 1999-02-24 Zeneca Ltd Chemical compounds
GB9914022D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
GB9914025D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
GB9914024D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
EP1453806B1 (en) * 2001-12-03 2007-12-19 F. Hoffmann-La Roche Ag Aminotetralin derivatives as muscarinic receptor antagonist
CN100349862C (zh) 2002-11-25 2007-11-21 先灵公司 大麻素受体配体
WO2005037830A1 (en) 2003-10-10 2005-04-28 Wyeth Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands
AU2005234596B8 (en) 2004-04-13 2011-06-16 Incyte Holdings Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US7378415B2 (en) 2004-09-30 2008-05-27 Roche Palo Alto Llc Benzoxazine and quinoxaline derivatives and uses thereof
BRPI0515835A (pt) * 2004-12-21 2008-08-12 Hoffmann La Roche derivados de tetralina e de indano e seus usos
KR20070121028A (ko) * 2005-03-29 2007-12-26 뉴론 파마슈티칼즈 에스. 피. 에이. 치환된 아미노알킬- 및 아미도알킬-벤조피란 유도체
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
WO2007051735A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
JP2009541248A (ja) 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホンアミジルテトラリン誘導体及びそれらの使用
WO2007147763A1 (en) 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonyl naphthalene derivatives and uses thereof
KR101066306B1 (ko) 2006-06-20 2011-09-20 에프. 호프만-라 로슈 아게 테트랄린 및 인데인 유도체 및 이들의 용도
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
AU2011216950A1 (en) 2010-02-16 2012-08-23 Pfizer Inc. (R)-4-((4-((4-(tetrahydrofuran-3-yloxy) benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
PE20181003A1 (es) * 2015-09-28 2018-06-26 Genentech Inc Compuestos terapeuticos y sus metodos de uso
MX2024000313A (es) 2021-07-09 2024-03-06 Plexium Inc Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD113545A5 (OSRAM) * 1973-03-30 1975-06-12
DE3064285D1 (en) * 1979-09-28 1983-08-25 Beecham Group Plc Chromanol derivatives, a process for their preparation and a pharmaceutical composition comprising them
DK691488A (da) * 1987-12-14 1989-06-15 Beecham Group Plc Hidtil ukendte forbindelser
DK286990D0 (da) * 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
PL176250B1 (pl) * 1991-11-05 1999-05-31 Smithkline Beecham Corp Sposób wytwarzania pochodnych indanu
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals

Also Published As

Publication number Publication date
DE69715865T2 (de) 2003-08-07
AU3495397A (en) 1998-01-21
JP2009040778A (ja) 2009-02-26
KR20000022380A (ko) 2000-04-25
ES2179353T3 (es) 2003-01-16
DE69715865D1 (de) 2002-10-31
JP2000514060A (ja) 2000-10-24
CA2258044C (en) 2007-09-04
CA2258044A1 (en) 1998-01-08
EP0912534A1 (en) 1999-05-06
WO1998000412A1 (en) 1998-01-08
ATE224884T1 (de) 2002-10-15
HUP9904167A2 (hu) 2000-05-28
IL127858A0 (en) 1999-10-28
HUP9904167A3 (en) 2000-07-28
EP0912534B1 (en) 2002-09-25
NZ333322A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
CA2258044C (en) Muscarinic antagonists
US5935958A (en) Muscarinic antagonists
WO1998000412A9 (en) Muscarinic antagonists
EP0811002B1 (en) Benzylpiperidines and piperazines as muscarinic antagonists
AU732096B2 (en) Ether muscarinic antagonists
EP0912515B1 (en) 1,4-di-substituted piperidines as muscarinic antagonists
RU2065859C1 (ru) Производные 2-(4-гидроксипиперидино)-1-алканола и производные 2-(4-гидроксипиперидино)-1-алканона
NO870078L (no) Diarylalkyl-substituerte alkylaminer, fremgangsmaate til deres fremstilling, deres anvendelse samt legemidler som inneholder dem.
CA2199621A1 (en) Substituted aryl piperazines as neurokinin antagonists
NZ212856A (en) Glutarimide derivatives and pharmaceutical compositions
AU2003243089B2 (en) Novel compounds, their use and preparation
JP2003509494A (ja) ムスカリン拮抗薬
WO2005094896A2 (en) Targeted serotonin reuptake inhibitors
EP3980420B1 (en) Imidazopyrazine derivatives and the use thereof as medicament
CA2212895C (en) Benzylpiperidines and piperazines as muscarinic antagonists
CN101141959B (zh) 作为甘氨酸转运体1(GlyT-1)抑制剂用于治疗神经学和神经精神病学障碍的2,5-二取代的苯甲酮衍生物
CN102060875A (zh) 新型喹唑啉衍生物、制备方法和用途
SK137597A3 (en) 1-£'omega'-(3,4-dihydro-2-naphthalenyl)alkyl| cyclic amine derivatives, process for producing the same, and medicinal composition containing the same
HU230761B1 (hu) Új, szelektív 5HT6-receptorgátló benzofurán-származékok és eljárás előállításukra
MXPA99001500A (en) Ether muscarinic antagonists
HK1018776B (en) Muscarinic antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired